Gabapentin
Product Images NDC 68788-6461

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-6461). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 1

A formula chart illustrating the calculation of creatinine clearance (CLCr) based on factors including age in years, body weight in kilograms, serum creatinine in mg/dL, and a multiplication factor of 0.85 for female patients.*

FDA Label Image

Gabapentin 10

FDA Label Image

Gabapentin 13

Drug facts panel for Gabapentin Capsules 100 mg by Preferred Pharmaceuticals Inc., including dosage instructions in English and Spanish, storage warnings, and federal law caution about drug transfer. The label mentions the manufacturer as Actavis Pharma, Inc., and includes lot and batch number fields as well as spaces for insurance and product identification.*

FDA Label Image

Gabapentin 2

Gabapentin 300 mg capsules bottle label from Preferred Pharmaceuticals Inc. The amber bottle has a white child-resistant cap and a label with product name, strength, dosage form, and labeler information. The visible portion of the label includes dosing instructions and warnings in fine print.*

FDA Label Image

Gabapentin 3

FDA Label Image

Gabapentin 4

FDA Label Image

Gabapentin 5

Chemical structure diagram of gabapentin, showing a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxymethyl group (CH2CO2H).*

FDA Label Image

Gabapentin 6

Line chart showing mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The X-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The Y-axis shows mean pain scores from 0 to 10. Gabapentin group shows a decreasing pain score trend, while placebo remains relatively stable.*

FDA Label Image

Gabapentin 7

A line graph displaying mean pain scores over seven weeks, comparing placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks including a 3-week titration and a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10. Gabapentin groups show decreasing pain scores compared to placebo over time.*

FDA Label Image

Gabapentin 8

A bar chart comparing percentage outcomes between placebo (PBO) and Gabapentin (GBP) at different dosages across two studies. Study 1 shows 12% for PBO and 29% for GBP 3600 mg, with statistical significance indicated. Study 2 shows 14% for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg, also with statistical significance markers (p < 0.01 and p < 0.001).*

FDA Label Image

Gabapentin 9

A scatter plot graph comparing difference percentage versus daily dose (mg) for Gabapentin across three studies labeled a, b, and c. The x-axis shows daily dose from 600 to 1800 mg, and the y-axis shows percentage difference from 2 to 22%. Each study is represented by a different color-coded square marker, showing variations in percentage difference at different doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.